The central focus of the Cytogenetics Shared Resource (CSR) is to provide cytogenetic and molecular cytogenetic analysis of human and animal model research samples. These samples may be in the form of cultured cells, fresh or frozen tissue, paraffin-embedded sections, or tissue microarrays (TMAs). Specific cell types include tumor cell lines, xenograft cells, hybrid cells from chimeric animal models, neural stem cells, and mouse embryonic fibroblasts, among others. The CSR provides specialized services including cell culture, routine cytogenetic analysis, chromosome breakage analysis, interphase and metaphase Fluorescence in situ Hybridization (FISH), Spectral Karyotyping (SKY) analysis of human and mouse metaphases, and homebrew FISH Probe Production. This last service provides novel FISH probes that are specific to investigators needs and are usually not commercially available. These probes are then used for FISH analysis studies. The CSR is expanding this service beyond homebrew enumeration FISH probes by creating custom translocation/fusion probes, break-apart probes, and multi-color FISH probes to ultimately assist in developing strategic probes that become clinical diagnostic and prognostic markers of disease. Other services provided by the CSR to meet the needs of investigators include utilization of the CSR laboratory for slide processing and fluorescent microscope and imaging system use. Briefly, applications of CSR services include: to characterize the clonality of tumor specimens;to determine the origin of a specific tumor culture (i.e., mouse vs. human), to aid in the identification of genetic regions important for the development of specific malignancies, and to map the location of DMA sequences, genes, or transgene insertions. With the recognition that cancer is a genetic disease, many cancer researchers, including scientists in the Mayo Clinic Cancer Center (MCCC), require access to CSR services. This Shared Resource is utilized by 9 of the 12 Cancer Center Programs. Approximately 66% of CSR users are CCSG members and represent 92% of the overall utilization.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-39
Application #
8465658
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$92,053
Indirect Cost
$28,324
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
DuBois, Steven G; Mosse, Yael P; Fox, Elizabeth et al. (2018) Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res 24:6142-6149
Farber, Benjamin A; Lalazar, Gadi; Simon, Elana P et al. (2018) Non coding RNA analysis in fibrolamellar hepatocellular carcinoma. Oncotarget 9:10211-10227
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Dasari, Surendra; Newsom, Sean A; Ehrlicher, Sarah E et al. (2018) Remodeling of skeletal muscle mitochondrial proteome with high-fat diet involves greater changes to ?-oxidation than electron transfer proteins in mice. Am J Physiol Endocrinol Metab 315:E425-E434

Showing the most recent 10 out of 1129 publications